CHANCE Investigators Selected Research

Clopidogrel (Plavix)

1/2023	Association Between CYP2B6 Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack.
3/2020	The association of white matter hyperintensities with stroke outcomes and antiplatelet therapy in minor stroke patients.
1/2020	Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE.
1/2020	Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.
1/2020	Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
12/2018	Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
1/2018	High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis.
11/2017	Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack: The CHANCE Study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
6/2017	Recurrent Stroke in Minor Ischemic Stroke or Transient Ischemic Attack With Metabolic Syndrome and/or Diabetes Mellitus.
1/2017	Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With CYP2C19 Genetic Variants.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

CHANCE Investigators Research Topics

Disease

21	Stroke (Strokes) 01/2024 - 09/2010
16	Transient Ischemic Attack 01/2024 - 09/2010
7	Ischemic Stroke 01/2020 - 07/2013
5	Hemorrhage 01/2023 - 07/2013
2	Pathologic Constriction (Stenosis) 01/2018 - 09/2015
1	Hepatocellular Carcinoma (Hepatoma) 12/2023
1	Overweight 01/2020
1	Infarction (Infarctions) 01/2020
1	Obesity 01/2020
1	Chronic Renal Insufficiency 12/2018
1	Hyperglycemia 11/2017
1	Diabetes Mellitus 06/2017
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2017
1	Hemorrhagic Stroke 07/2013
1	Cerebral Hemorrhage 09/2010

Drug/Important Bio-Agent (IBA)

20	Clopidogrel (Plavix)FDA Link 01/2023 - 09/2010
15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2023 - 09/2010
4	AlbuminsIBA 01/2024 - 03/2015
3	Cytochrome P-450 CYP2C19IBA 01/2020 - 01/2017
3	C-Reactive ProteinIBA 01/2018 - 07/2015
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 03/2015
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2017 - 09/2010
1	apatinibIBA 12/2023
1	Monoclonal AntibodiesIBA 12/2023
1	camrelizumabIBA 12/2023
1	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 01/2023
1	HomocysteineIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 11/2017
1	CD40 Ligand (CD40L)IBA 07/2015

Therapy/Procedure

15	Therapeutics 01/2024 - 07/2013
1	Secondary Prevention 01/2023
1	Glycemic Control 01/2017